API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The collaboration aims to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-56248), albuterol/fluticasone combination, currently in Phase 3 clinical trials for patients with asthma.
Lead Product(s): Fluticasone Propionate,Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TEV-56248
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Launch Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 01, 2024
Details:
The net proceeds will be used to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-56248), albuterol/fluticasone combination, currently in Phase 3 clinical trials for patients with asthma.
Lead Product(s): Fluticasone Propionate,Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TEV-56248
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Abingworth
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 01, 2024
Details:
Airsupra (albuterol/budesonide) formerly known as PT027, is a first-in-class SABA/ICS. It is now available as the first and only FDA-approved anti-inflammatory rescue option for asthma.
Lead Product(s): Salbutamol Sulphate,Budesonide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Airsupra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
Albuterol sulfate inhalation powder is first and only breath-actuated, digital SABA inhaler, which is used for prevention of bronchospasm related to exercise-induced or reversible obstructive airway disease.
Lead Product(s): Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Proair HFA-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2023
Details:
Airsupra (albuterol/budesonide), is a first-in-class SABA/ICS rescue treatment for asthma in the US. It is an inhaled, fixed-dose combination of albuterol, a SABA, and budesonide, and has been developed in a pMDI using AstraZeneca’s Aerosphere delivery technology.
Lead Product(s): Salbutamol Sulphate,Budesonide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Airsupra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avillion LLP
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
PT027 (albuterol/budesonide) is a potential first-in-class, pressurised metered-dose inhaler (pMDI), fixed-dose combination rescue medication in the US containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS).
Lead Product(s): Salbutamol Sulphate,Budesonide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PT027
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avillion LLP
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
Result showed adults and children aged 13 and older with uncontrolled asthma using ProAir Digihaler (albuterol sulfate) and integrated system had 85.3% higher odds of improving their asthma control after 3 months compared with those using standard-of-care albuterol inhalers.
Lead Product(s): Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ProAir Digihaler
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Study evaluated the effect of ProAir Digihaler System on asthma control versus standard of care as measured by Asthma Control Test, and explored use of the ProAir Digihaler System to help support patient-physician interactions for asthma management versus standard of care.
Lead Product(s): Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ProAir Digihaler
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
PT027 (Albuterol Sulfate) is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an inhaled corticosteroid (ICS), in the US, being developed by Avillion and AstraZeneca under an agreement.
Lead Product(s): Salbutamol Sulphate,Budesonide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PT027
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
ProAir Digihaler (albuterol sulfate) inhalation powder is a prescription medicine used in people ≥4 years of age for the treatment or prevention of bronchospasm in people who have reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Lead Product(s): Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ProAir Digihaler
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Full results from positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, demonstrated a statistically significant reduction in risk of a severe exacerbation versus albuterol rescue in patients with asthma.
Lead Product(s): Salbutamol Sulphate,Budesonide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PT027
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2022
Details:
ProAirDigihaler (albuterol sulfate) inhalation powder is first and only breath-actuated, digital SABA inhaler with built-in flow sensors that detect, record and store objective data showing how often and how well patients use their rescue inhaler, measured by inspiratory flow.
Lead Product(s): Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ProAir Digihaler
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
PT027 significantly reduced the risk of severe exacerbations compared to albuterol in patients with moderate to severe asthma in MANDALA trial when used as a rescue medicine in response to symptoms.
Lead Product(s): Salbutamol Sulphate,Budesonide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PT027
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avillion LLP
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021
Details:
Albuterol sulfate is used to treat or prevent bronchospasm in patients four years and older with reversible obstructive airway disease, such as asthma, and to prevent exercise-induced bronchospasm.
Lead Product(s): Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Proventil HFA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 16, 2021
Details:
ProAir® HFA, Generic albuterol sulfate inhalation aerosol is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Lead Product(s): Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2020